United Therapeutics Corporation (NASDAQ:UTHR) Receives $648.33 Average PT from Analysts

Shares of United Therapeutics Corporation (NASDAQ:UTHR) have been given an average rating of “Moderate Buy” by the thirteen research firms that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $648.3333.

A number of equities research analysts recently issued reports on UTHR shares. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Weiss Ratings cut shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday. JPMorgan Chase & Co. raised their price target on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Morgan Stanley set a $516.00 price target on shares of United Therapeutics in a report on Thursday, May 7th. Finally, TD Cowen restated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st.

Insider Buying and Selling

In other news, Director Jan Malcolm sold 325 shares of United Therapeutics stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $550.59, for a total value of $178,941.75. Following the completion of the transaction, the director owned 450 shares of the company’s stock, valued at $247,765.50. The trade was a 41.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $518.96, for a total value of $4,930,120.00. Following the completion of the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at $168,372,939.28. The trade was a 2.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 492,833 shares of company stock worth $273,056,767. Insiders own 8.60% of the company’s stock.

Institutional Trading of United Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Geneos Wealth Management Inc. lifted its stake in shares of United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 85 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its position in shares of United Therapeutics by 18.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock worth $127,000 after buying an additional 70 shares during the last quarter. Jump Financial LLC acquired a new position in shares of United Therapeutics during the second quarter worth $277,000. Cerity Partners LLC raised its stake in United Therapeutics by 77.3% in the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock valued at $3,691,000 after buying an additional 5,600 shares during the last quarter. Finally, Bank of Nova Scotia raised its position in shares of United Therapeutics by 6.9% in the 2nd quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after purchasing an additional 105 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Down 0.3%

UTHR stock opened at $516.31 on Tuesday. United Therapeutics has a twelve month low of $287.64 and a twelve month high of $609.35. The firm has a market capitalization of $21.92 billion, a PE ratio of 19.06, a P/E/G ratio of 1.73 and a beta of 0.59. The stock’s 50 day moving average is $542.59 and its 200-day moving average is $533.07.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). The business had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same period in the prior year, the firm posted $6.63 EPS. On average, equities research analysts anticipate that United Therapeutics will post 26.65 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.